ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
EMA review confirms risks of Abbvie and Biogen's Zinbryta outweigh benefits
May 25, 2018The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacov
Pharma Sources Insight January 2025
